2014-04-28 16:34:02 - Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 - a new market research report on companiesandmarkets.com
Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022 - We have released our new report, "Semaglutide (Type 2 Diabetes) - Forecast and Market Analysis to 2022". The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians´ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.
Semaglutide is a long-acting GLP-1 analog being developed by Novo Nordisk, currently in Phase III
clinical trials. Two Bristol-Myers Squibb medicines (short-acting Byetta and long-acting Bydureon), Novo Nordisk´s long-acting Victoza and Sanofi´s short-acting Lyxumia are marketed drugs in the same class of treatment for type 2 diabetes.
- Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Semaglutide including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Semaglutide for the top ten countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Semaglutide performance
- Obtain sales forecast for Semaglutide from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)
Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..
Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..
Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.comâs online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.